Company profile
PRECIGEN, INC.
NASDAQ:PGENBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PAPZIMEOS | approved | $53.1MQ2 2026 | 1 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03751007 | phase1_2 | completed | 2018-10-24 | 2021-10-13 | Precigen Actobio T1D, LLC | A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) |
| NCT04724980 | phase1_2 | active_not_recruiting | 2021-03-16 | 2024-06-05 | Precigen, Inc | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis |
| NCT03907527 | phase1 | active_not_recruiting | 2019-04-30 | 2024-12-15 | Precigen, Inc | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| NCT06157151 | phase2 | recruiting | 2025-11-11 | 2026-11-11 | Precigen, Inc | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer |
| NCT03927261 | phase1 | active_not_recruiting | 2019-05-20 | 2024-08-01 | Precigen, Inc | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125832 | 2025-08-14 | BLA | PRECIGEN, INC. | |||||
Loading… | ||||||||